Cell therapies hold promise in a wide range of diseases. However, several challenges limit their therapeutic potential, including development of critically short telomeres. During the cell therapy manufacturing process, normal human cells are forced to expand rapidly, resulting in significant telomere shortening. This effect may reduce a cell's lifespan and limits the long-term favorable outcome for patients. Telos Biotech has developed an approach that is designed to rapidly and safely lengthen the shortest telomeres, helping to ensure that engineered cells are therapeutically robust: Telovance™.

Telovance™ is a protein complex that is delivered during the ex-vivo expansion stage of cell manufacturing. Telovance™ is designed to enhance the next generation of cell therapies and enable more sophisticated, multi-step cell engineering technologies. Our team will partner with you to incorporate Telovance™ into any cell therapy manufacturing process and support regulatory submissions.